SCHEMBL1744284

SCHEMBL1744284

CC(C)(C)OC(=O)c1ccc(CCCCCCCCCCC(=O)NCCCC(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.54
TSHR P16473 1/20 0.54
ITGB3 P05106 1/20 0.54
ITGA2B P08514 1/20 0.54
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
RXRA P19793 2/20 0.46
NR1H2 P55055 2/20 0.46
NR1H3 Q13133 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1743772 0.89 MAPT (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL21577923 0.88 HSD17B10 (0.55) ITGB3ITGA2BHDAC3HDAC4HDAC1
SCHEMBL4076440 0.87 ITGB3 (0.42) LMNATSHRITGB3ITGA2BCA1
SCHEMBL10396391 0.82 LMNA (0.65) LMNATSHRITGB3ITGA2BHDAC3
SCHEMBL4090552 0.82 CA1 (0.43) ITGB3ITGA2BCA1CA2
SCHEMBL4190835 0.79 ITGB3 (0.43) ITGB3ITGA2BHDAC1HDAC2HDAC6
SCHEMBL4179442 0.79 ITGB3 (0.43) ITGB3ITGA2BHDAC1HDAC2HDAC6
SCHEMBL4183681 0.79 CYP4A11 (0.52) RXRANR1H2NR1H3HSD17B10
SCHEMBL1743875 0.79 CYP4A11 (0.52) RXRANR1H2NR1H3HSD17B10
SCHEMBL14952381 0.78 LMNA (0.85) LMNATSHRHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2024390-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-08-19 EP disclosed
EP-2386572-B1 Insulin derivative NOVO NORDISK AS (DK) 2015-07-08 EP disclosed
US-8933021-B2 Insulin derivative NOVO NORDISK A/S (DK) 2015-01-13 US disclosed
US-8796205-B2 Insulin derivative NOVO NORDISK A/S (DK) 2014-08-05 US disclosed
EP-2015770-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2012-09-26 EP disclosed
EP-2386572-A1 Insulin derivative Novo Nordisk A/S (DK) 2011-11-16 EP disclosed
US-8039101-B2 Radio-opaque dental prosthetic member Societe de Recherches Techniques Dentaires-R.T.D. (FR) 2011-10-18 US disclosed
US-20090239785-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-09-24 US disclosed
US-20090105121-A1 Insulin Derivative NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
EP-2024390-A1 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2009-02-18 EP disclosed
WO-2007128815-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239785-A1 Insulin Derivative IAPP, INSR, GPR119 LMNA 2556/4885TSHR 1025/4885ITGB3 4146/4885
US-20090105121-A1 Insulin Derivative INSR, IAPP, GPR119 LMNA 2327/4885TSHR 196/4885ITGB3 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.